- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05249218
Impact of Fruit and Vegetables in PKU
February 18, 2022 updated by: Alex Pinto
Impact of Fruits and Vegetables on Metabolic Control in Children With PKU
In the UK, some fruits and vegetables are permitted without measurement in the diets of people with phenylketonuria (PKU).
It is proven that fruits and vegetables containing phenylalanine (Phe) up to 75mg/100g (e.g.
carrots, sweet potato, tomatoes) do not affect blood Phe control but it is unknown to what extent fruits and vegetables containing Phe from 76-100mg/100g (e.g.
cauliflower, broccoli, beansprouts and asparagus) increase blood Phe levels.
In addition, there is very little information about how differently animal and vegetable protein affect blood Phe levels.
It is believed that plant protein may have less bioavailability and therefore have less impact on blood Phe control.
The investigators aim is to perform a randomized controlled study over 21 weeks in children (5-12y) with PKU.
Children will be studied during five different time periods, examining the effect on blood Phe control when increasing Phe intake from vegetables/fruits containing Phe from 76-100 mg/100g vs. animal sources.
At the end of the study, fruits and vegetables containing 76- 100mg Phe/100g will continue to be given as "exchange-free" for 6 months.
This is a practical, cost effective study and should bring benefit to all people with PKU following a very restrictive diet both within the UK and throughout the world.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
- Other: Phase B - Extra 1 Phe exchange from fruits/vegetables containing Phe from 76-100mg/100g
- Other: Phase C - Extra 2 Phe exchanges from fruits/vegetables containing Phe from 76-100mg/100g
- Other: Phase D - Extra 1 Phe exchange from milk or yoghurt
- Other: Phase E - Extra 2 Phe exchanges from milk or yoghurt
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
West Midlands
-
Birmingham, West Midlands, United Kingdom, B4 6NH
- Birmingham Women's and Children's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
5 years to 12 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- PKU patients diagnosed by NBS and BH4 deficiencies;
- Early and continuously treated;
- Adherent to their prescribed PKU diet consisting of a protein-restricted diet and Phe-free amino acid based protein substitute;
- In good general health as evidenced by medical history;
- Able to provide written informed consent/assent (parent/child);
- Able to comply with the study protocol and take study product according to the opinion of the PI;
- Patients with good metabolic control (age 5-12y, 120-360μmol/L) with 3 out of 4 levels within range prior to consent (if 2 of 4 above target range but one close to the upper limit, PI to decide if patient can enter the study).
Exclusion Criteria:
- Concomitant diseases / disorders such as renal or gut disease / disorders and diabetes;
- Dislikes fruits and vegetables containing 76-100 mg of Phe/100g e.g.brocolli or cauliflower;
- Treated with BH4 (sapropterin);
- Presence of intercurrent infection;
- Patients with poor metabolic control (age 5-12y, >360μmol/L).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group starting intervention with vegetable protein
Phase A followed by Phases B, C, D, E.
|
Usual low Phe diet + 60g fruits/vegetables containing Phe from 76-100mg/100g
Usual low Phe diet + 120g fruits/vegetables containing Phe from 76-100mg/100g
Usual low Phe diet but 1 x 50 mg extra Phe exchange from milk or yoghurt
Usual low Phe diet but 2 x 50 mg extra Phe exchange from milk or yoghurt eaten daily
|
Active Comparator: Group starting intervention with animal protein
Phase A followed by Phases D, E, B, C.
|
Usual low Phe diet + 60g fruits/vegetables containing Phe from 76-100mg/100g
Usual low Phe diet + 120g fruits/vegetables containing Phe from 76-100mg/100g
Usual low Phe diet but 1 x 50 mg extra Phe exchange from milk or yoghurt
Usual low Phe diet but 2 x 50 mg extra Phe exchange from milk or yoghurt eaten daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Blood Phe levels three times a week of patients with PKU taking extra 1 or 2 exchanges of fruits and vegetables containing 76-100mg of Phe/100g during 4 weeks each.
Time Frame: 8 weeks
|
8 weeks
|
Blood Phe levels three times a week of patients with PKU taking extra 1 or 2 exchanges of animal protein during 4 weeks each.
Time Frame: 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Blood Phe levels three times a week with PKU taking fruits and vegetables containing 76-100mg of Phe/100g without measurement during 6 months.
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 20, 2019
Primary Completion (Actual)
June 30, 2021
Study Completion (Actual)
June 30, 2021
Study Registration Dates
First Submitted
June 10, 2021
First Submitted That Met QC Criteria
February 18, 2022
First Posted (Actual)
February 21, 2022
Study Record Updates
Last Update Posted (Actual)
February 21, 2022
Last Update Submitted That Met QC Criteria
February 18, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18/BC/DTS/NO/215
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Phenylketonurias
-
Lumos DiagnosticsAptatek BiosciencesRecruiting
-
SanofiRecruiting
-
Children's Hospital of Fudan UniversityHedu Biotechnology (Shanghai) Co., LTDRecruiting
-
University Hospital, GrenobleRecruitingMetabolic Diseases | PhenylketonuriaFrance
-
APR Applied Pharma Research s.a.Recruiting
-
University Children's Hospital, ZurichUniversity Children's Hospital Basel; UChildrenVienna; Insel Gruppe AG, University...RecruitingPhenylketonuriasSwitzerland
-
University Hospital, LilleNot yet recruiting
-
Emory UniversityBioMarin PharmaceuticalRecruitingPhenylketonuriasUnited States
-
Vitaflo International, LtdCompleted
-
Vitaflo International, LtdJohannes Gutenberg University Mainz; Kreiskliniken ReutlingenCompleted